6 citations
,
August 2021 in “Clinical Epidemiology” Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
3 citations
,
November 1998 in “PubMed” 37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
September 2003 in “Reactions Weekly”
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
4 citations
,
June 2024 in “Animals” Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.
March 2005 in “The Nurse Practitioner”
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
11 citations
,
April 2018 in “Journal of Dermatology” Dutasteride safely treats hair loss without harming sexual function.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
March 2005 in “European Urology Supplements”
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
March 2002 in “Hair transplant forum international” Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
June 1982 in “Revista Colombiana de Obstetricia y Ginecología” El acetato de ciproterona trata problemas androgénicos como hirsutismo, acné, seborrea y alopecia con diferentes dosis y combinaciones.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
20 citations
,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
Cyproterone acetate is an effective treatment for women with acne, hair loss, and excessive hair growth.